- Home
- MYI vs TRVI Comparison
MYI vs TRVI Comparison
Compare MYI & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYI
- TRVI
- Stock Information
- Founded
- MYI 1992
- TRVI 2011
- Country
- MYI United States
- TRVI United States
- Employees
- MYI N/A
- TRVI N/A
- Industry
- MYI Investment Bankers/Brokers/Service
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- MYI Finance
- TRVI Health Care
- Exchange
- MYI Nasdaq
- TRVI Nasdaq
- Market Cap
- MYI 723.2M
- TRVI 629.8M
- IPO Year
- MYI N/A
- TRVI 2019
- Fundamental
- Price
- MYI $10.45
- TRVI $6.51
- Analyst Decision
- MYI
- TRVI Strong Buy
- Analyst Count
- MYI 0
- TRVI 8
- Target Price
- MYI N/A
- TRVI $19.31
- AVG Volume (30 Days)
- MYI 256.7K
- TRVI 1.0M
- Earning Date
- MYI 01-01-0001
- TRVI 05-08-2025
- Dividend Yield
- MYI 4.81%
- TRVI N/A
- EPS Growth
- MYI N/A
- TRVI N/A
- EPS
- MYI N/A
- TRVI N/A
- Revenue
- MYI N/A
- TRVI N/A
- Revenue This Year
- MYI N/A
- TRVI N/A
- Revenue Next Year
- MYI N/A
- TRVI N/A
- P/E Ratio
- MYI N/A
- TRVI N/A
- Revenue Growth
- MYI N/A
- TRVI N/A
- 52 Week Low
- MYI $9.32
- TRVI $2.30
- 52 Week High
- MYI $11.70
- TRVI $7.39
- Technical
- Relative Strength Index (RSI)
- MYI 44.98
- TRVI 54.36
- Support Level
- MYI $10.37
- TRVI $6.08
- Resistance Level
- MYI $10.51
- TRVI $6.47
- Average True Range (ATR)
- MYI 0.11
- TRVI 0.34
- MACD
- MYI -0.01
- TRVI -0.02
- Stochastic Oscillator
- MYI 38.69
- TRVI 67.01
About MYI Blackrock MuniYield Quality Fund III Inc
BLACKROCK MUNIYIELD QUALITY FUND III, INC. is a investment management company. Its investment objective is to provide shareholders with a high level of current income exempt from U.S. federal income taxes as is consistent with its investment policies and prudent investment management. The company invests in various sectors such as Transportation; Utilities; Health; Education; Tobacco and others.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.